Ahmet Demirkazık

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

Hakan Akbulut, Güngör Utkan, Bülent Yalçın et al. · Journal of Surgical Oncology · 2006 · 108 citations

Medicine, Oncology, Pharmacology +14

Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey

Yüksel Ürün, Güngör Utkan, Ayten Cangır et al. · Asian Pacific Journal of Cancer Prevention · 2013 · 46 citations · Full text

Medicine, Oncology, Pathology +15

ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma

Yüksel Ürün, Nuriye Özdemir, Güngör Utkan et al. · Asian Pacific Journal of Cancer Prevention · 2012 · 32 citations · Full text

Medicine, Hematology, Oncology +13